

# **New Advances in Diagnosis and Treatment of Atopic Disorders**

*An Essay  
Submitted for Partial Fulfillment for the  
Master Degree in Clinical Pathology  
By*

**Amani Saeed Ali Mohammed**

*(M.B.,B.Ch)  
Faculty of Medicine – Cairo University*

*Supervised By*

**Prof. Dr. Laila Abd Alaala Elshawarby**

*Professor of Clinical Pathology  
Faculty of Medicine – Ain Shams University*

**Prof. Dr. Manal Zaghloul Mahran**

*Professor of Clinical Pathology  
Faculty of Medicine – Ain Shams University*

**Dr. Abeer Al Sayed Ali Shehab**

*Lecturer of Clinical Pathology  
Faculty of Medicine – Ain Shams University*

Faculty of Medicine  
Ain Shams University  
2005

## **ACKNOWLEDGEMENT**

*Thanks to God who have lightened my path to become a humble student of a noble profession, and granted me the ability to accomplish this work.*

*I wish to express my deep gratitude and appreciation to, **Professor Dr. Laila Abd Alaala Elshawarby, Professor of Clinical Pathology, Faculty of Medicine–Ain Shams University**, who gave me the honor of working under her meticulous supervision.*

*Words can never express my hearty thanks and indebtedness to, **Professor Dr. Manal Zaghloul Mahran, Professor of Clinical Pathology, Faculty of Medicine–Ain Shams University**, for her continuous encouragement, excellent guidance, and powerful support.*

*I gratefully acknowledge **Dr. Abeer Al Sayed Ali Shehab, lecturer of Clinical Pathology, Faculty of Medicine–Ain Shams University**, for her generous help, expert advice, unlimited support and assistance throughout this work.*

*I would like to express my sincerest gratitude and thanks to my husband who always provide me with great support and encouragement, and to my family. Special prayers for my father that God will reward him in his heavens.*

## Contents

● Introduction and aim of the work .....	1
● Review of Literature .....	3
Chapter 1: An overview on Atopy .....	3
I. Type I Hypersensitivity Allergic Reaction .....	4
A. Atopic Allergens .....	4
1. Pollen Allergens .....	5
2. Mold Allergens .....	7
3. Arthropod Allergens .....	7
4. Food Allergens .....	8
5. Animal Allergens .....	8
B. Pathophysiology of Type I Allergy .....	8
1. The Concept of Allergic Sensitization .....	8
2. Pathophysiology of the Established Allergic Memory Immune Response .....	12
C. Cells Involved in the Allergic Immune Response .....	14
1. APC .....	14
a. Dendritic Cells (DCs) .....	14
b. Macrophages .....	15
2. T Lymphocytes .....	15

3. B Lymphocytes .....	21
4. Mast Cells .....	22
5. Basophils .....	24
6. Eosinophils .....	29

## **II. Diagnosis of Atopy .....31**

### **A. In Vivo Tests .....31**

1. Skin Tests .....	31
a. Scratch .....	32
b. Prick .....	33
c. Intradermal Tests .....	33
2. Provocation Tests .....	35
a. Nasal Provocation .....	35
b. Oral provocation .....	37
c. Bronchial Provocation .....	38

### **B. In vitro tests .....38**

1. Indications of in vitro testing .....	39
2. Contraindication .....	39
3. Types .....	40
a. Total serum IgE .....	40
b. Allergen specific IgE .....	41
i. Radioallergo sorbant test (RAST) .....	41
ii. Cellulose Polymer Activated (CAP) System .....	42
iii. UNICAP 100 .....	43
iv. Immunoblotting .....	44

### **-Recombinant Allergens in Diagnosis of Atopy .....44**

## **Chapter 2: Treatment of Atopic diseases .....49**

### **I. Allergen Specific Immunotherapy (SIT) .....49**

-Historical Prespective .....49

#### **A. Mechanisms of SIT .....50**

Model 1: SIT Shifts the Th2-dominated Allergen-specific  
Immune Toward Th1 Response .....51

Model 2: SIT Induce Allergen-specific T cell Tolerance  
(Anergy) .....51

Model 3: SIT has Vaccination Character and Induces an  
Immune Response that Counteracts the Allergic  
Immune Response .....52

#### **B. Types of Immunotherapy .....55**

1. Conventional Immunotherapy .....55

2. Unconventional Immunotherapy .....56

#### **C. Indications of Immunotherapy .....57**

1. Conditions for which Effectiveness of Immunotherapy  
has been Demonestreted .....59

a. Allergic Rhinitis .....59

b. Asthma .....59

c. Insect Hypersensitivty .....60

2. Conditions for which Effective of Immunotherapy has  
not been Demonestreted .....61

3. Controversial or unclear Indications .....61

D. Risks Associated with Immunotherapy .....	62
E. Selection of Relevant Allergen Extracts .....	64
1. Source of Allergen Extracts .....	64
2. Allergen Standardization .....	65
3. Allergen Potency and Stability .....	66
<b>II. New Techniques and Future Directions .....</b>	<b>68</b>
A. Allergen Modification .....	68
1. Hypoallergens .....	68
a. Chemically Modified Allergens .....	70
i. Allergoids .....	70
ii. Maleylated Allergens .....	71
iii. Allergen-ISS Conjugates (AIC) .....	72
b. Naturally Occurring Hypoallergens .....	75
c. Engineered Hypoallergens .....	76
i. Site-Directed Mutants .....	78
ii. Deletion Mutants .....	79
iii. Fragments .....	79
iv. Oligomers .....	80
v. Chimeras .....	81
2. Synthetic Peptides .....	83
a. B-cell Epitope-derived Peptides .....	83
b. T-cell Epitope-containing Peptides .....	84
c. Mimotopes .....	86
3. Protein Fusions .....	88
B. Customized Allergen DNA Vaccines .....	89

-Strategies to Increase Safety of Allergen DNA Vaccines ..	92
1. DNA Vaccines Translating Hypoallergenic Allergen Derivatives .....	94
2. Ubiquitination: A Routine Strategy to Produce Hypoallergenic DNA Vaccines .....	95
3. Vaccine Dose Reduction with Self-replicating Vaccines .....	96
4. Improvement of Immunogenicity and Tailor-made Immune Responses .....	98
a. Harmonization of the Codon Usage .....	99
b. Th1/Th2 Modulation of Allergy DNA Vaccines ....	100
5. DNA Multivaccines .....	101
C. Alternative Treatments and Supporting Adjuvants for SIT .....	103
1. Possible Role of Th Switch and Cytokines .....	103
2. Possible Role of Tregs in Allergen Immunotherapy ..	106
● <b>References .....</b>	<b>110</b>
● <b>Summary .....</b>	<b>135</b>
● <b>Arabic Summary</b>	

## LIST OF ABBREVIATIONS

Ag	Antigen.
AIC	Allergen ISS conjugates.
APC	Antigen presenting cells.
AS	Allergen specific.
AU	Allergy unit.
BAU	Biological allergy unit.
BCG	Bacille Calmette Guerin.
C	Complement.
CAP	Cellulose polymer activated within a capsule.
CCL11	Eotaxin.
CCR3	Eotaxin Receptor.
CD	Cluster of differentiation.
cDNA	Complementary DNA.
CPG	Unmethylated cytosine-guanosine.
CRD	Component resolved diagnosis.
CRIT	Component resolved immunotherapy.
CTLA-4	Cytotoxic T-Lymphocyte antigen-4.
DCs	Dendritic cells.
EAR	Early asthmatic response.
EIA	Enzyme immunosorbant assay.
ELISA	Enzyme-linked immunosorbent assay.
ER	Endoplasmic reticulum.
FcεRI	High-affinity receptor for IgE.
FcεRII	Low-affinity receptor for IgE.
FEV <sub>1</sub>	Forced expiratory volume in one second.
GM-CSF	Granulocyte monocyte-colony stimulating Factor.
HLA	Human leukocyte antigen.
ICAM-1	Intercellular adhesion molecule 1.



IFN	Interferons.
IgA	Immunoglobulin A.
IgE	Immunoglobulin E
IgG	Immunoglobulin G.
IL	Interleukin
IR	Index of reactivity.
ISSs	Immunostimulatory sequences.
IU	International unit.
LAB	Lactic acid bacteria.
LAR	Late asthmatic response.
LPRs	Late phase response.
LPS	Lipo Poly Saccharides.
LSPs	Long synthetic overlapping peptides.
LTB4	Leukotriene B4.
LTC4	Leukotriene C4.
MHC-I	Major histocompatibility complex class I.
MHC-II	Major histocompatibility complex class II.
MIP-1a	Macrophage inflammatory protein-1a.
MIP-1 $\alpha$	Macrophage inflammatory protein-1 $\alpha$ .
MRT	Modified RAST test.
NGF	Neutrophil growth factor.
NK	Natural Killer cell.
NMR	Nuclear magnetic resonance.
nsLTPs	Nonspecific lipid transfer proteins.
ODNs	Oligodeoxy- nucleotides.
PAF	Platelet activating factor.
PBMC	Peripheral blood monocytes.
PEG	Polyethylene glycol.
PRR	Pattern-recognition receptors.
RAST	Radioallergosorbent test.
RIA	Radioactive immunosorbant assay.
SIT	Allergen specific immunotherapy.

SRs	Scavenger receptors.
TCR	T-cell receptor.
TGF- $\alpha$	Transforming growth factor- $\alpha$ .
TGF- $\beta$	Transforming growth factor- $\beta$ .
Th	T-helper cells.
TLR	Toll-like receptor.
TNF	Tumor necrosis factor
TR	Therapeutic unit.
Tregs	Regulatory T cells.
VPF/ VEGF	Vascular permeability factor/ Vascular endothelial cell growth factor.

## LIST OF TABLES

<b>Table</b>	<b>Title</b>	<b>Page</b>
Table 1	A summary of the four types of allergy.	<b>3</b>
Table 2	Structure and biologic function of some allergens.	<b>6</b>
Table 3	Factors involved in allergic sensitization.	<b>9</b>
Table 4	Tregs that may be involved in prevention of allergy.	<b>19</b>
Table 5	Potential clinical application of CD25+CD4+ Tregs.	<b>21</b>
Table 6	Possible mechanisms of SIT.	<b>54</b>

## LIST OF FIGURES

<b>Figure</b>	<b>Title</b>	<b>Page</b>
Fig.1	The allergic immune response (top and middle panels). Mechanisms of allergic inflammation (bottom panel).	<b>11</b>
Fig.2	LPR scenario emphasizing the putative regulatory roles of basophils in allergic inflammation.	<b>28</b>
Fig.3	Possible advantages to the use of hypoallergens for SIT.	<b>69</b>
Fig.4	Examples of hypoallergens.	<b>77</b>
Fig.5	Synthetic peptides.	<b>87</b>
Fig.6	Customized allergens by protein fusion.	<b>89</b>
Fig.7	Potential mechanisms of conventional allergen immunotherapy.	<b>108</b>

## Introduction

Allergic atopic disorders, such as rhinitis, asthma, and atopic dermatitis, are the result of a systemic inflammatory reaction triggered by type 2 T helper (Th2) cell-mediated immune responses against 'innocuous' antigens (allergens) of complex genetic and environmental origin (**Romagnani, 2004**).

Allergic diseases are common, disabling and potentially life threatening that lead to production of excessive allergen-specific immunoglobulin E (IgE) (**Prescott and Jones, 2002**). The clinical manifestations of allergic diseases are often the same as with other diseases which makes their diagnosis difficult. Therefore, clinical practitioners often need a laboratory test that is capable of identifying them in a suitable manner with low costs, speed of execution, availability at most laboratories and a high level of sensitivity in identifying its target population (**Naspitz et al., 2004**).

Recent technological advances have provided a better understanding of underlying disease process and offered new potential therapeutic targets. New techniques include: peptide immunotherapy, allergen modification, allergen gene vaccination, and others (**Prescott and Jones, 2002**).

Immunotherapy is a therapeutic intervention in which the patient is administered increasing doses of an extract of specific allergen(s), to which the patient has been demonstrated to be allergic, in order to modulate the patient's immune response, thus, attenuate or eliminate the symptoms (**Bousquet et al., 1998**).

Vaccines are used in medicine as immune modifiers (**Bousquet et al., 1998**). Allergen vaccines are used in the diagnosis and treatment of allergic diseases as specific immunomodulatory therapy. In clinical practice, allergen vaccines have been shown to be effective in the treatment of allergy and anaphylaxis. Successful allergen immunotherapy is associated with a long-term decrease in antigen-specific IgE production, an increase in antigen-specific IgG production, a decrease in Th2 proliferation to antigen, and an increase in antigen-specific suppressor T cell activity (**Slater et al., 2000**).

## **Aim of the Work**

The aim of this study is to spot light on the diagnosis of atopic diseases and their new treatment modalities.

## An overview on Atopy

The term allergy was introduced by Clemens Von Pirquet in 1906 to describe overwhelming pathological reaction of the body due to intercurrent contact with antigens (Ags) (**Valenta et al., 2004**). Allergy is characterized by increased ability of some immunocompetent cells to respond to a group of ubiquitous Ags that activate the immune system after their inhalation, ingestion, or penetration through the skin (**Guerra et al., 2001**).

Combs and Gell, 1975 proposed a first detailed classification of allergic reactions in four types (I-IV) based on defined underlying pathomechanism (Table 1) (**Valenta et al., 2004**).

Type	(I) Immediate	(II) Cytotoxic	(III) Immune complex	(IV) Delayed
Ag	Pollens, molds, mites, drugs, and parasite	Cell surface tissue bound	Exogenous (bacteria, fungi) and autoantigen	Cell/tissues bound
Mediators	IgE & mast cells	IgG, IgM and complement	IgG, IgM, IgA And complement	Tc, TD, activated macrophage & lymphocytes
Time taken for reaction to develop	15-30 min	Rapid	4-12 hours	12-48 hours
Diseases & condition produced	Eczema, urticaria, anaphylaxis	Haemolytic anaemia, transfusion reaction	Autoimmune diseases (e.g., SLE)	Contact dermatitis, leprosy, T.B

**Table1:** A summary of the four types of allergy (**Ghamriny, 2003**).